---
title: "Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280643855.md"
description: "Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin"
datetime: "2026-03-26T13:49:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280643855.md)
  - [en](https://longbridge.com/en/news/280643855.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280643855.md)
---

# Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

Hua Medicine Doubles Diabetes Drug Revenue and Secures Hong Kong Approval for Dorzagliatin

### Related Stocks

- [02552.HK](https://longbridge.com/en/quote/02552.HK.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)

## Related News & Research

- [Hua Medicine Announces 2025 Annual Results](https://longbridge.com/en/news/280735000.md)
- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [JPMorgan lowers 2026 gold forecast, still sees rally towards $6,000 on renewed demand](https://longbridge.com/en/news/286715908.md)